Kedbumin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high incidence of hypoalbuminemia, long standing clinical use of albumin, critical care expansion, burn and trauma management needs, hospital based infusion reliance.

The growth in the forecast period can be attributed to rising intensive care admissions, growth in liver disease prevalence, expansion of surgical procedures, increasing plasma collection capacity, improved critical care infrastructure. Major trends in the forecast period include continued demand for albumin therapies, growth in critical care volume expansion, rising use in liver and trauma management, expansion of plasma derived therapeutics, strengthening hospital infusion practices.

The rising prevalence of chronic diseases is expected to drive the growth of the Kedbumin market in the future. Chronic diseases are long-term conditions that persist for three months or more and may worsen over time. The increasing prevalence of these diseases is largely attributed to sedentary lifestyles, with reduced physical activity contributing to higher rates of conditions such as diabetes and cardiovascular diseases. Kedbumin plays a vital role in managing complications like ascites and spontaneous bacterial peritonitis by improving circulatory function and reducing fluid accumulation. For example, in June 2023, a report from Kidney Research UK, a UK-based non-profit organization, revealed that approximately 7.2 million people in the UK are living with chronic kidney disease, representing over 10% of the population. Of these, 3.25 million are in the advanced stages, while an additional 3.9 million are in the early stages. By 2033, the number of individuals affected by chronic kidney disease is expected to rise to 7.61 million. Therefore, the growing prevalence of chronic diseases is driving the expansion of the Kedbumin market.

The growing aging population is also expected to fuel the Kedbumin market moving forward. The aging population, consisting of individuals aged 65 and older, is a demographic trend driven by increased life expectancy and declining birth rates. This shift is supported by advancements in healthcare, medical technology, and improved living conditions. Kedbumin, a plasma-derived albumin solution, plays a key role in supporting the aging population by managing conditions such as hypovolemia, hypoalbuminemia, and other related complications, thus improving health outcomes and recovery. For example, in January 2024, statistics published by the Population Reference Bureau (PRB), a U.S.-based nonprofit organization, projected that the number of Americans aged 65 and older will increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. Additionally, their proportion of the total population is expected to grow from 17% to 23%. As a result, the growing aging population is contributing to the continued growth of the Kedbumin market.

In July 2023, Kedrion Biopharma Inc., a leading Italy-based producer of human blood plasma-derived therapies, completed its merger with Prometic BioTherapeutics Inc. The merger aims to strengthen Kedrion's U.S. commercial structure and improve its position in the plasma-derived therapeutics market. By combining their resources, the merger enhances operational efficiency and supports key products such as Kedbumin. It integrates manufacturing and distribution capabilities, allowing for more streamlined operations. Prometic BioTherapeutics Inc., a U.S.-based plasma operations company, contributed complementary expertise and infrastructure to the merged organization, making it stronger and more competitive within the market.

Major companies operating in the kedbumin market are Kedrion SpA.

North America was the largest region in the kedbumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kedbumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kedbumin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the kedbumin market by increasing costs associated with plasma sourcing, albumin purification, and cold chain transportation. These impacts are most significant in hospital and specialty clinic settings, particularly in regions dependent on imported plasma derived products. Higher tariffs can affect affordability and availability in critical care environments. However, tariffs are also encouraging regional plasma fractionation, domestic albumin production, and long term self sufficiency in essential supportive therapies.

The kedbumin market research report is one of a series of new reports that provides kedbumin market statistics, including kedbumin industry global market size, regional shares, competitors with a kedbumin market share, detailed kedbumin market segments, market trends and opportunities, and any further data you may need to thrive in the kedbumin industry. This kedbumin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Kedbumin is a therapeutic product used to manage and treat conditions related to protein deficiency, particularly in patients with hypoalbuminemia or other related disorders. It is a clear, slightly viscous solution with an amber, yellow, or green hue, stabilized with the inclusion of 0.08 mmol sodium caprylate and 0.08 mmol sodium acetyltryptophan per gram of albumin.

The primary indications for Kedbumin include the treatment of hypoalbuminemia, fluid resuscitation, management of liver diseases, treatment of burns and trauma, and more. Hypoalbuminemia is a condition characterized by low albumin levels in the blood, which can lead to various health complications. Kedbumin is available in injectable formulations and lyophilized powders for reconstitution. It is used across a broad range of patient demographics, including pediatric, adult, and geriatric patients. The product is distributed through various channels, including direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. It is utilized by a variety of end users, such as hospitals, specialty clinics, home healthcare providers, pharmaceutical and biotechnology companies, and research institutions.

The kedbumin market consists of sales of kedbumin products for medical and therapeutic use. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.